Antineoplastic Combined Chemotherapy Protocols - Research News and Information

Thursday, January 08, 2009

Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma.

30 Oct 2008 PURPOSE: To determine the response, toxicity, and survival for children with progressive or recurrent medulloblastoma and germinoma using a single myeloablative course of chemotherapy supported by autologous hematopoietic stem cells. PATIENTS AND ... Read more...

Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma.

30 Oct 2008 BACKGROUND: Increasing numbers of children with advanced neuroblastoma are achieving cure. We describe the clinical late effects specific to survivors of stage IV neuroblastoma all similarly treated using tandem autologous peripheral blood stem ... Read more...

Characteristics and outcomes of medulloblastoma in adults.

30 Oct 2008 BACKGROUND: Adult medulloblastoma is a rare disease for which there is no internationally accepted standard of care. Treatment regimens have typically been modeled after pediatric protocols. We sought to review the presentation, management, and ... Read more...

Learn Faster Today      Improve your study skills

Latest indexed articles for 'Antineoplastic Combined Chemotherapy Protocols'

These are the very latest articles for this heading:

• Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma. 30 Oct 2008
• Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma. 30 Oct 2008
• Characteristics and outcomes of medulloblastoma in adults. 30 Oct 2008
• Prognostic factors in children with Hodgkin disease. 30 Oct 2008
• Complete second look operation and radiotherapy in locally advanced non-alveolar rhabdomyosarcoma in children: A report from the AIEOP soft tissue sarcoma committee. 30 Oct 2008
• The guardians' perspective on paediatric cancer treatment in Malawi and factors affecting adherence. 30 Oct 2008
• Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol. 30 Oct 2008
• Pulmonary function studies in children treated by chemoradiotherapy and stem cell transplantation. 30 Oct 2008
• CD20+ T-cell lymphoma: clinicopathologic analysis of 9 cases and a review of the literature. 30 Oct 2008
• Cystoid macular edema secondary to albumin-bound paclitaxel therapy. 30 Oct 2008
• Re: Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? 26 Oct 2008
• Docetaxel for hormone-refractory prostate cancer. 23 Oct 2008
• Toll-like receptor-4 is expressed in meningiomas and mediates the antiproliferative action of paclitaxel. 13 Oct 2008
• Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. 13 Oct 2008
• Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. 13 Oct 2008
• Clofarabine combinations as acute myeloid leukemia salvage therapy. 13 Oct 2008
• Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. 13 Oct 2008
• Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. 13 Oct 2008
• Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. 13 Oct 2008
• Clofarabine: in search of combinations for the treatment of patients with high-risk acute myeloid leukemia. 13 Oct 2008

See a longer list of these articles.

Technical information about 'Antineoplastic Combined Chemotherapy Protocols'

Definition: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.

Descriptor UI: D000971

Alternative terms: Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Agents, Combined; Agent, Combined Antineoplastic; Agents, Combined Antineoplastic; Antineoplastic Agent, Combined; Combined Antineoplastic Agent; Drug Combinations, Antineoplastic; Antineoplastic Drug Combinations; Antineoplastic Drug Combination; Combinations, Antineoplastic Drug; Drug Combination, Antineoplastic; Combined Antineoplastic Agents; Anticancer Drug Combinations; Anticancer Drug Combination; Drug Combination, Anticancer; Drug Combinations, Anticancer; Antineoplastic Combined Chemotherapy Regimens; Antineoplastic Chemotherapy Protocols; Antineoplastic Chemotherapy Protocol; Chemotherapy Protocol, Antineoplastic; Protocol, Antineoplastic Chemotherapy; Protocols, Antineoplastic Chemotherapy; Chemotherapy Protocols, Antineoplastic; Cancer Chemotherapy Protocols; Cancer Chemotherapy Protocol; Chemotherapy Protocol, Cancer; Chemotherapy Protocols, Cancer; Protocol, Cancer Chemotherapy; Protocols, Cancer Chemotherapy;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; economics; history; immunology; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications;

Tree Number: E02.183.750.500; E02.319.077.500; E02.319.310.037;

History Note: 2002(1984)

Technical Notes: administered simultaneously or sequentially; coordinate IM with specific antineoplastic agents /admin (NIM)